Traws Pharma Reports Positive Phase 2 COVID-19 Results for Ratutrelvir, Faces FDA Clinical Hold for Influenza Drug Tivoxavir Marboxil

summarizeSummary

Traws Pharma announced positive final Phase 2 results for its COVID-19 treatment, ratutrelvir, but also disclosed an FDA clinical hold on its influenza drug, tivoxavir marboxil, due to safety concerns.

check_boxKey Events

• Positive Phase 2 COVID-19 Study Results for Ratutrelvir

  Traws Pharma completed analysis of its 90-patient Phase 2 study for ratutrelvir, an oral, ritonavir-free COVID-19 treatment. Results showed fewer treatment-related adverse events (10% vs. 23.3% for PAXLOVID®), quicker symptom resolution in PAXLOVID®-ineligible patients (HR 1.31; p=0.018), and no viral rebounds, confirming a differentiated profile.

• FDA Clinical Hold for Tivoxavir Marboxil IND

  The FDA placed Traws Pharma's US Investigational New Drug (IND) application for tivoxavir marboxil, an influenza therapy, on clinical hold due to concerns regarding mutagenicity data. Formal communication from the FDA with mitigation steps is expected by March 16, 2026.

• Tivoxavir Marboxil Development Continues Ex-US

  Despite the US clinical hold, Traws Pharma plans to advance tivoxavir marboxil into a healthy volunteer study in Australia and a Human Influenza Prophylaxis Challenge Study in the UK, leveraging pre-clinical data showing increased exposure with a new tablet formulation.

auto_awesomeAnalysis

This filing presents a mixed but highly impactful update for Traws Pharma, a clinical-stage biopharmaceutical company. The positive completion of analysis for the Phase 2 COVID-19 study of ratutrelvir, demonstrating a differentiated profile with fewer adverse events and no viral rebounds compared to PAXLOVID®, is a significant clinical advancement. This could position ratutrelvir as a valuable treatment, especially for PAXLOVID®-ineligible patients. However, the simultaneous announcement of an FDA clinical hold for tivoxavir marboxil due to mutagenicity data concerns is a substantial setback for its US development as an influenza prophylactic. While the company plans to continue ex-US studies, the FDA hold introduces regulatory uncertainty and delays for a key pipeline asset, which is a material risk for a small biotech.